BioSpace3d
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
WebMD4d
FDA Approves New Drug for Life-Threatening Heart Condition
The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...
Daily2d
Kidney Function Decline Identified as Key Mortality Risk Marker in Transthyretin Amyloid Cardiomyopathy: JAMA
UK: A recent retrospective cohort study has highlighted the critical role of kidney function in patients diagnosed with ...
FDA approves Palo Alto biotech's heart disease drug
The stock market responded positively to the company's announcement, with its share price leaping more than 28% following the ...
Opinion | A Short Lesson in Drug Competition
Whoever says the Food and Drug Administration is too cozy with Big Pharma isn’t paying attention to the bonanza of new ...
US FDA approves BridgeBio's drug for rare heart condition (Nov 22)
The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...
BioSpace5d
Days After BridgeBio Approval, FDA Agrees to Review Alnylam’s Amvuttra in ATTR-CM
The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...
BioPharma Dive7d
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved ...
Monthly Prescribing Reference4d
Vutrisiran Under Review for Transthyretin Amyloid Cardiomyopathy
Vutrisiran, a transthyretin-directed small interfering RNA therapeutic, is currently approved under the brand name Amvuttra ® for the treatment of polyneuropathy manifestations of hereditary ...
GlobalData on MSN5d
FDA approves BridgeBio’s Attruby for ATTR-CM treatment
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...
Monthly Prescribing Reference4d
Attruby Approved for Cardiomyopathy of Transthyretin-Mediated Amyloidosis
The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...
Intellia Gets RMAT Designation From FDA For Nex-z In ATTR Amyloidosis With Polyneuropathy; Stock Up
Intellia Therapeutics, Inc. (NTLA), a clinical-stage gene editing company, Monday said that the U.S. Food and Drug Administration or ...